Zai’s Sandler heads to Mirati
Plus Huang becomes Zai CSO and updates from Aadi, VectorY, Fulcrum and Xenon
Alan Sandler joined Mirati Therapeutics Inc. (NASDAQ:MRTX) as EVP and CMO after departing Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688), which has hired Peter Huang as CSO. Huang was SVP of discovery research for Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL), before which he worked on the discovery of small molecules at Pfizer Inc. (NYSE:PFE). Sandler was at Genentech Inc. before he joined Zai as president and head of global development oncology in 2020. Mirati also said founder, President and Head of R&D Charles Baum would retire in 2Q23.
Aadi Bioscience Inc. (NASDAQ:AADI) said COO Brendan Delaney will succeed Neil Desai as president and CEO when Desai becomes executive chair on Jan. 1, 2023. Delaney joined Aadi in 2021 from Constellation Pharmaceuticals Inc., where he was chief commercial officer. Desai founded Aadi and invented the company’s mTOR inhibitor Fyarro nab-sirolimus, which FDA approved to treat malignant perivascular epithelioid cell tumor in November 2021. ...